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EDITORIAL COMMENT
Endotoxin Attacks the
Cardiovascular System
Black Death at the Tollgate*
Wilbur Y. W. Lew, MD, FACC
San Diego, California
Bacteria have attacked the cardiovascular system since time
immemorial. The propensity for pathogenic bacteria to
effect cardiovascular collapse and death has shaped human
history. Black Death, caused by Yersinia pestis, killed tens of
millions in China, the Middle East, and decimated one-
third of the European population in the 14th century. More
recently, fatalities from toxic Escherchia coli and the sinister
threat of bio-weapons serve as poignant reminders of the
dangers of severe bacterial infections.
The propinquity of bacteria as part of the normal flora
poses an ever-present threat. Bacteria colonize humans in
symbiotic and commensal relationships that are neither
beneficial nor detrimental. However, disruption of normal
barriers (e.g., skin or gastrointestinal tract) permits bacteria
to invade into the bloodstream (bacteremia) and release
toxins (endotoxemia). Severe infections induce systemic
inflammatory responses (sepsis) that predispose to multior-
gan failure, hypotension (septic shock), and death.
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Severe sepsis causes as many deaths as does acute myo-
cardial infarction (MI) in the U.S., with an annual cost of
$16.7 billion (1). The incidence rates of sepsis and deaths
related to sepsis have increased significantly over the past 20
years (2). This has been related to an increase in invasive
procedures and predisposing conditions, such as aging,
chronic diseases, and immunosuppression (e.g., cancer,
HIV, transplants). The high mortality from sepsis and
septic shock (e.g., 30% to 50%) has motivated a search for
more effective treatments based on pathogenesis (3,4).
In 1892, Richard Pfeiffer related the pathogenicity of
bacteria to endotoxins, which others subsequently charac-
terized as lipopolysaccharide (LPS) (5,6); LPS is the major
component comprising 75% of the outer cell wall of gram-
negative bacteria (6). Lysis of a single gram-negative bac-
terium releases approximately 106 LPS molecules. Minus-
cule amounts of LPS activate coagulation and complement
cascades and effector cells of innate immunity to release a
cascade of mediators that neutralize invading bacteria. The
transmembrane receptor responsible for LPS sensing and
signal transduction remained elusive until this past decade,
when it was identified as toll-like receptor 4 (TLR-4) in
mammals. The TLR-4 resembles Toll proteins of Drosoph-
ila, an ancient, evolutionarily conserved antimicrobial sys-
tem in vertebrates, invertebrates, and plants. These pattern
recognition receptors identify and defend against invasion
by foreign pathogens, such as LPS.
The LPS activates innate immune-response cells through
TLR-4 (e.g., monocytes, macrophages, neutrophils, and
endothelial cells) with exuberant production of cytotoxic
mediators that may contribute to organ damage in sepsis
(3,7). Cells that express TLR-4, such as cardiac myocytes,
are susceptible to direct damage by LPS, independently of
mediators. Low levels of LPS depress cardiac myocyte
contractility, impair beta-adrenergic responsiveness, and
induce cell death by apoptosis to contribute to cardiac
depression in sepsis (8,9).
Key mediators have been targeted for therapy to improve
survival in sepsis. Based on the success of preclinical studies,
clinical trials have evaluated inhibitors of LPS, cytokines
(e.g., TNF and IL-1), oxygen radicals, platelet activating
factor, prostaglandins, bradykinin, and nitric oxide
(7,10,11). Unfortunately, the majority of clinical trials failed
to improve mortality, creating a “graveyard for pharmaceu-
tical companies” (although recent novel approaches such as
activated protein C have shown promise) (11). The wide-
spread failure of therapeutic trials has been disheartening,
raising concerns that survival has improved little since the
introduction of antibiotics over 50 years ago. This despair
may be unwarranted because the causes, context, and
definition of sepsis have undergone major transformations.
Epidemiologic data have documented advances in therapy
with decreased in-hospital mortality in the U.S. over the
past 20 years (from 28% to 18%), even though the total
number of deaths has increased (2).
It is important to understand why favorable results from
experimental models have not translated into improved
outcomes in therapeutic trials. The approach of identifying
and inhibiting specific immune mediators warrants critical
reappraisal. It may be unrealistic to expect that a “magic
bullet” targeting a single pathway can abrogate the sequelae
of sepsis. Early therapy that interrupts proximal pathways
can be successful in preclinical studies, but this is difficult to
achieve in clinical sepsis. Patients are often in the later
stages of sepsis before the diagnosis is established and
therapy is contemplated. By this time, LPS has activated a
cascade of interacting mediators with redundant pathways
that induce tissue damage (3). Organ failure adds another
dimension of complexity with additional mechanisms for
inducing tissue damage. At this stage, it may be too late to
alter the clinical course by blocking a single or few branches
in this complex network.
Preclinical studies utilize homogeneous models of sepsis
with controlled timing and dose of the insult, treatment,
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host factors (e.g., age and genetics), and mortality. This
uniformity does not exist in clinical trials. Including patients
at low risk for death makes it more difficult to prove that
therapy improves mortality (10). In fact, inhibiting normal
innate immune mechanisms in low-risk patients may have
deleterious effects. In the clinical setting, few criteria exist
for titrating doses or determining if therapy is contraindi-
cated.
Heterogeneity of the target population makes it difficult
to evaluate the effectiveness of therapy (7). Patients vary in
their susceptibility, etiology, and severity of sepsis and
responses to therapy. Elderly patients are more prone to
severe sepsis, with potential racial and gender differences
(1,2). Genetic polymorphisms of TLR-4 predispose to more
severe infections (12). Risk stratification schemes that take
into account the cause, severity, and host responses are
needed to identify patients who are most likely to benefit
from specific therapies. This approach has been employed
with success in other complex conditions, such as cancer and
coronary artery disease.
In this issue of the Journal, Pleiner et al. (13) examined
LPS effects on vascular responsiveness. Low doses of LPS
injected into normal subjects impaired forearm blood flow
responses to vasoconstrictors (norepinephrine, angiotensin
II, and vasopressin) and lowered vitamin C levels after 4 h.
These abnormalities were corrected by infusing high doses
of the antioxidant, vitamin C. This suggests that LPS
impairs vasoconstrictor responses by inducing oxidative
stress.
These results may add to the armamentarium to treat
vasodilation with endotoxemia in conditions such as sepsis.
Sepsis is the most common cause of vasodilatory shock, with
refractoriness to vasoconstrictors a harbinger of death (14).
Optimizing hemodynamics and tissue oxygenation early in
sepsis decreases multiorgan failure and improves survival
(15). However, several issues need to be addressed before
the results from this model can be applied to sepsis. This
cautious approach is not unique for the Pleiner et al. (13)
study but is mandated by the frequent failure to extrapolate
favorable preclinical results into improved outcomes in
therapeutic trials.
First, infusing low doses of endotoxin into normal vol-
unteers is not a model of sepsis. This mimics subacute
endotoxemia, which occurs with low circulating levels of
LPS in conditions such as decompensated heart failure (16),
cardiopulmonary bypass surgery (17), chronic infections
(e.g., respiratory, gastrointestinal, genitourinary), and smok-
ing (18). It is unknown whether oxidative stress with
impaired vasoconstrictor response occurs in these condi-
tions, but that would be an interesting implication of these
results.
Second, oxidative stress in sepsis involves several reactive
oxygen species (e.g., superoxide, hydrogen peroxide, hy-
droxyl radicals) and antioxidative defense mechanisms (e.g.,
superoxide dismutase, catalase, vitamins C and E, and
glutathione) (19). Scant clinical data prove that antioxidant
therapy improves survival. This may relate to the need to
identify the specific type and source of reactive oxygen
species involved and/or requirement to use multiple anti-
oxidants.
Third, impairments were measured 4 h after LPS expo-
sure in healthy subjects. Oxidative stress may impair vaso-
constrictor responses early after LPS, but this may not be
the sole or dominant mechanism with higher levels of LPS
or in sepsis. Sepsis activates multiple pathways that induce
vasodilatory shock, including nitric oxide (14). Nitric oxide
is not involved in this model, but that does not exclude an
important role in sepsis. Antioxidant therapy that is effective
in normal subjects with normal endothelial function may
not be beneficial in patients with preexisting and/or ac-
quired endothelial dysfunction in sepsis.
Fourth, refractory vasodilation and oxidative stress may
be important in some, but not all, cases of sepsis. Cardio-
vascular dysfunction is present in 25% of patients with
severe sepsis (1). The broad application of antioxidant
therapy for all patients with sepsis may not improve out-
come or adequately test the hypothesis that reducing oxi-
dative stress effectively treats refractory hypotension. The
subgroup most likely to benefit from therapy needs to be
defined along with appropriate end points (e.g., use of
pressors and mortality).
Finally, there is a potential for treatment to worsen
outcome. For example, a phase III clinical trial was aborted
when it was found that inhibiting nitric oxide increased
mortality in sepsis (despite promising preclinical results)
(20). Nitric oxide and reactive oxygen species are protective
in controlling the proliferation of invading bacteria. These
mediators may cause tissue damage, but routine inhibition
might increase mortality. Oxidative stress impairs vasocon-
strictor responses, but it may be undesirable to subvert this
defense mechanism except in cases of refractory hypoten-
sion.
Bacterial attacks on the cardiovascular system have had a
storied history. It required five centuries after the Black
Death to establish the role of endotoxin, several decades to
relate this to LPS, and recent developments to understand
how LPS activates cells through Toll-like receptors. Reduc-
tionist models have provided invaluable insights, but trans-
lating these results into improving survival from sepsis poses
unresolved challenges. However, advances in supportive
care and adjunctive therapies provide encouragement that
progress is being made in solving these complex problems.
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